Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
Andrew Bottomley(European Organisation for Research and Treatment of Cancer), Alexander M.M. Eggermont(University Medical Center Utrecht), Zvonko Kusić(Sisters of Charity Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Corneel Coens(European Organisation for Research and Treatment of Cancer), Cornelis J.A. Punt(Utrecht University), Ulrich Keilholz(German Cancer Research Center), Stefan Suciu(St James's University Hospital), W. Kruit(Erasmus MC), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), François Salès(Institut Jules Bordet), Reinhard Dummer(University Hospital of Zurich), Poulam Patel(Radboud University Nijmegen), Jeremy Marsden(NIHR Surgical Reconstruction and Microbiology Research Centre), Rona M. MacKie(University of Glasgow), Alan Spatz(Jewish General Hospital), Martin Gore(Imperial College London), Alessandro Testori(European Organisation for Research and Treatment of Cancer)
Cited by 116
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k